Revenue and EBITDA Growth
Revenue from continuing operations increased by 6%, and consolidated adjusted EBITDA increased by 36% compared to Q3 2024.
Stock Repurchase and Cash Position
Repurchased $5 million of stock since the last conference call, with an additional $12 million authorized. Unrestricted cash and cash equivalents were strong at $29.7 million.
Digital Marketing and Technology Initiatives
Launched a national marketing campaign and strengthened digital marketing efforts with SEO improvements, resulting in a 20% to 40% increase in organic search traffic. Patient-facing mobile app adoption reached 18% of new patients with over 178,000 downloads.
Progress in Refranchising Strategy
Entered into an agreement to sell 45 corporate clinics in Southern California for $4.5 million, with ongoing negotiations for the remaining 33 corporate clinics.